drug_type
RELEVANT_DRUG
intervention_type
Gene-engineered cellular immunotherapy (CAR-T)
drug_description
Autologous gene-engineered CAR T-cell product expressing a CD70-specific CAR with co-expression of CXCR2 (IL-8 receptor) to enhance trafficking to IL-8–rich glioblastoma, administered as a single IV infusion in dose escalation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Interleukin-8B
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-engineered to express a CD70-specific chimeric antigen receptor and the IL-8 receptor CXCR2. CXCR2 enhances chemotaxis toward IL-8–rich glioblastoma, improving tumor homing and infiltration. CAR engagement of CD70 on tumor cells activates T-cell effector functions, leading to targeted cytotoxic killing (perforin/granzyme) and cytokine release against CD70-positive glioblastoma cells.
drug_name
Ex-vivo expanded autologous IL-8 receptor (CXCR2)–modified CD70 CAR T cells (8R-70CAR)
nct_id_drug_ref
NCT05353530